🏛️ Verified NIH Record • Updated 2026-05-14
MYLUNG Consortium Study Protocol 2 (NCT05644808)
Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: US Oncology Research
🩺 Plain-English Summary (8th-Grade Level)
This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Who can join: Review the eligibility criteria below.
Location: Southern Cancer Center, PC — Daphne, Alabama
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Southern Cancer Center, PC — Daphne, Alabama
- Rocky Mountain Cancer Center — Denver, Colorado
- Woodlands Medical Specialists, PA — Pensacola, Florida
- Illinois Cancer Specialists — Niles, Illinois
- Maryland Oncology Hematology, P.A. — Silver Spring, Maryland
- Minnesota Oncology Hematology, P.A. — Minneapolis, Minnesota
- New York Oncology Hematology, P.C. — Albany, New York
- Oncology Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
- Willamette Valley Cancer Institute and Research Center — Eugene, Oregon
- Texas Oncology - West Texas — Abilene, Texas
- Texas Oncology- DFWW — Arlington, Texas
- Texas Oncology-Dallas Presbyterian Hospital — Dallas, Texas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- Texas Oncology - Fort Worth Cancer Center — Fort Worth, Texas
- Texas Oncology-McAllen — McAllen, Texas
- Texas Oncology- Northeast Texas — Tyler, Texas
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Virginia Oncology Associates — Newport News, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.